欢迎访问行业研究报告数据库

报告分类

重点报告推荐

当前位置:首页 > 行业导航

找到报告 33769 篇 当前为第 11 页 共 3377

所属行业:医药制造业

  • 101.医药生物行业:医疗器械与服务近期相关政策跟踪及解读-中信建投

    [医药制造业] [2024-12-06]

    近期国家医保局发布多项医改政策。医疗服务价格立项指南政策有助于推动AI辅助阅片、云胶片及部分新技术在医 疗机构中的应用。检查检查结果互认有助于减少重复检验检查,检查检验价格下调或影响部分医院的相关业务收入,部分医院 将主动控制设备采购成本,选择性价比更高的国产品牌,并为新技术、新设备、新耗材加快放量留出空间,继续看好创新能力 强、推进进口替代、国际化业务布局的国产医疗器械龙头投资机会。

    关键词:医疗器械;AI辅助阅片;云胶片;新技术;医疗机构中的应用
  • 102.生物医药行业:以血制品行业盈利模型,窥其投资价值几何-太平洋证券

    [医药制造业] [2024-12-06]

    本篇报告以血制品企业盈利模型的角度展开,即公司盈利=采浆量× 吨浆毛利-期间费用,同时考虑到集采风险、重组生物制品对血制品的替 代风险,逐项拆解,来洞察行业趋势及探究血制品企业的投资价值。

    关键词:血制品企业;盈利模型;集采风险;重组生物制品;替代风险;逐项拆解;投资价值
  • 103.全球多模态成像市场(2024-2029年)

    [医药制造业,信息传输、软件和信息技术服务业] [2024-11-29]

    Multimodal imaging has revolutionized the field of medical diagnostics, offering clinicians a comprehensive view of anatomical structures and physiological processes through the integration of multiple imaging modalities. The concept of multimodal imaging dates to the early 20th century when pioneers in radiology began combining different imaging techniques to obtain complementary information about diseases and injuries. The advent of X-ray technology in the late 19th century laid the foundation for modern medical imaging, paving the way for innovations in magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, and nuclear medicine.

    关键词:多模态成像;医学诊断领域;成像模式;解剖结构;生理过程;互补信息
  • 104.全球医疗保健领域临床数据分析市场2023年

    [医药制造业] [2024-11-29]

    The clinical data analytics market in healthcare is defined based on the revenues generated from the various solutions used in different end-use across the globe. The analysis is based on the market insights captured through secondary and primary research. The market also covers major factors impacting the growth of the market in terms of drivers and restraints. The scope of the study has been segmented based on the deployment type (cloud and on-premises), organization size (large enterprises, and small & medium enterprises (SMEs)), and end users (MedTech, pharmaceutical and life sciences, public health and government, and other end users (payers and providers) across the globe.

    关键词:医疗保健领域;临床数据分析市场;解决方案;影响市场增长
  • 105.全球家禽疫苗市场报告2023年

    [医药制造业,农、林、牧、渔业] [2024-11-29]

    As per the scope of the report, poultry vaccines help prevent any particular disease by boosting the poultry animals’ immune system to produce antibodies, which fight against organisms.

    关键词:家禽疫苗;增强;家禽动物;免疫系统;抗生物;抗体;预防任何特定疾病
  • 106.全球草坪草生物防治剂市场2023年

    [医药制造业] [2024-11-29]

    Biocontrol agents are the organisms or microorganisms that control the plant pathogen in turf grass. The global turf grass biocontrol agent market is segmented by form and geography. The report offers market size and forecast by value (USD million) for the above segments.

    关键词:生物防治剂;控制草坪;草中植物病原体;生物或微生物;生物防治剂市场
  • 107.全球维生素和氨基酸市场报告2024年

    [医药制造业] [2024-11-29]

    The scope of the report includes the application of vitamins and amino acids in food and beverage, pharmaceuticals, and animal feed industries across the globe.

    关键词:维生素;氨基酸;全球食品饮料;药品和动物饲料
  • 108.全球子宫肌瘤治疗市场规模和份额分析增长趋势和预测(2024-2029年)

    [医药制造业] [2024-11-28]

    The uterine fibroids market (henceforth referred to as the market studied unless specified otherwise) is estimated to be USD 4,564.8 million in 2024. It is expected to reach USD 6,927.7 million by 2029, registering a CAGR of 8.7% from 2024 to 2029 (henceforth referred to as the forecast period).

    关键词:全球子宫肌瘤治疗;市场规模;份额分析增长;医疗保险
  • 109.全球制药业2024 年第二季度

    [医药制造业] [2024-11-27]

    Bloomberg Law News - Amgen Seeks Speedy Ruling Against Colorado Drug Pricing Board - 26/6/2024 Drugmaker Amgen Inc. will suffer “concrete harm” unless a federal judge quickly enjoins Colorado’s drug pricing board from moving forward with a payment cap for the autoimmune treatment Enbrel, the company argued in a filing.

    关键词:制药商安进公司;自身免疫治疗药物 Enbrel ;设定支付上限
  • 110.全球制药业2024年第二季度

    [医药制造业] [2024-11-27]

    First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting Positive results from the ECHO Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and showed a favourable trend in overall survival (OS) compared to standard-of-care chemoimmunotherapy (bendamustine plus rituximab) in previously untreated patients with mantle cell lymphoma (MCL). These results will be presented today in a late-breaking oral presentation at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain (#LBA3439).

    关键词:制药业;化工业;销量增长
首页  上一页  ...  6  7  8  9  10  11  12  13  14  15  ...  下一页  尾页  
© 2016 武汉世讯达文化传播有限责任公司 版权所有 技术支持:武汉中网维优
客服中心

QQ咨询


点击这里给我发消息 客服员


电话咨询


027-87841330


微信公众号




展开客服